The impact of beta-blockers on mortality in stable angina: a meta-analysis

Scottish Medical Journal
H L Huang, K A A Fox

Abstract

Beta-blockers are recommended as first-line symptomatic treatment for stable angina. However, their impact on mortality outside the context of myocardial infarction is unknown. We performed a meta-analysis of all randomized trials of beta-blockers in stable angina. Medical databases and cardiology journals were searched for relevant randomized clinical trials. The primary outcome was cardiovascular mortality, separately considering trials of beta-blockers versus placebo and beta-blockers versus other antianginals. We conducted a subgroup analysis on cardioselective versus non-cardioselective beta-blockers and calcium channel antagonists versus nitrates. We calculated odds ratios (ORs) and confidence intervals (CIs) using Peto's method. We found no statistically significant evidence that beta-blockers impact on mortality when compared with placebo (OR, 0.42; CI , 0.15-1.21) or other antianginals (OR, 0.98; CI, 0.86-1.10), or all others (OR, 0.97; CI, 0.86-1.09). There was a trend for cardioselective beta-blockers to have a greater improvement in mortality when compared with placebo and to have greater impact than non-calcium channel antagonists. Beta-blockers do not have statistically significant impact on mortality versus place...Continue Reading

References

Mar 1, 1985·Progress in Cardiovascular Diseases·S YusufP Sleight
Mar 26, 1982·JAMA : the Journal of the American Medical Association
Jun 1, 1999·JAMA : the Journal of the American Medical Association·P A HeidenreichM A Hlatky
Oct 23, 2002·Circulation·Milton PackerUNKNOWN Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group
Nov 22, 2005·Journal of the American Pharmacists Association : JAPhA·UNKNOWN Lewin Group
Feb 13, 2009·Expert Review of Cardiovascular Therapy·Graziano Riccioni

❮ Previous
Next ❯

Citations

Jul 30, 2014·The Canadian Journal of Cardiology·G B John ManciniRodney Zimmermann
Jul 19, 2014·Journal of the American College of Cardiology·Charlotte AnderssonMark A Hlatky
Apr 23, 2014·The Canadian Journal of Cardiology·Pierre LarochelleYves Lacourcière
Apr 21, 2016·Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række·Jan Erik OtterstadDag S Thelle
Feb 24, 2015·Lancet·Desmond G Julian, Stuart J Pocock
Jul 5, 2016·European Journal of Pharmacology·Louise E See HoeJason N Peart
Sep 18, 2016·Cardiovascular Drugs and Therapy·Udho Thadani
Jan 26, 2017·Drugs·Talla A RousanUdho Thadani
Jan 1, 2017·Indian Heart Journal·Sundeep MishraV K Bahl
Mar 31, 2017·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Csaba András Dézsi, Veronika Szentes
Jun 4, 2021·Current Cardiology Reports·Francesco MoroniLorenzo Azzalini

❮ Previous
Next ❯

Software Mentioned

Review Manager

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.